Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $32,217.15 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, March 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00.
• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Price Performance

HALO stock opened at $61.87 on Wednesday. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 0.42 and a beta of 1.32. The firm’s 50-day moving average price is $59.34 and its two-hundred day moving average price is $54.84. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth $69,000. Retirement Systems of Alabama increased its position in shares of Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after buying an additional 74,173 shares during the period. Shaker Investments LLC OH raised its stake in Halozyme Therapeutics by 12.3% in the fourth quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock worth $3,601,000 after buying an additional 8,249 shares in the last quarter. Foster & Motley Inc. lifted its holdings in Halozyme Therapeutics by 118.6% in the fourth quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after buying an additional 12,630 shares during the period. Finally, Jennison Associates LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at approximately $731,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on HALO shares. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.